Header Logo
Last Name

Adam S Duerfeldt

TitleAssistant Professor
InstitutionUniversity of Oklahoma, Norman
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of KansasPhD2011Medicinal Chemistry

    Collapse Research 
    Collapse research activities and funding
    R21EY028279     (DUERFELDT, ADAM SCOTT)Sep 1, 2017 - Aug 31, 2019
    Hit to Lead Optimization of a Systemically Available Treatment for Diabetic Retinopathy
    Role: Principal Investigator

    P20GM103640     (WEST, ANN H)Aug 1, 2012 - May 31, 2022
    Oklahoma COBRE in Structural Biology
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Li Y, Gardner JJ, Fortney KR, Leus IV, Bonifay V, Zgurskaya HI, Pletnev AA, Zhang S, Zhang ZY, Gribble GW, Spinola SM, Duerfeldt AS. First-generation structure-activity relationship studies of 2,3,4,9-tetrahydro-1H-carbazol-1-amines as CpxA phosphatase inhibitors. Bioorg Med Chem Lett. 2019 Jul 15; 29(14):1836-1841. PMID: 31104993.
      View in: PubMed
    2. Lavey NP, Shadid T, Ballard JD, Duerfeldt AS. Clostridium difficile ClpP Homologues are Capable of Uncoupled Activity and Exhibit Different Levels of Susceptibility to Acyldepsipeptide Modulation. ACS Infect Dis. 2019 Jan 11; 5(1):79-89. PMID: 30411608.
      View in: PubMed
    3. Dou XZ, Nath D, Shin Y, Ma JX, Duerfeldt AS. Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARa selective agonists: New leads for oculovascular conditions. Bioorg Med Chem Lett. 2018 09 01; 28(16):2717-2722. PMID: 29628329.
      View in: PubMed
    4. Que NLS, Crowley VM, Duerfeldt AS, Zhao J, Kent CN, Blagg BSJ, Gewirth DT. Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding. J Med Chem. 2018 04 12; 61(7):2793-2805. PMID: 29528635.
      View in: PubMed
    5. Li Y, Lavey NP, Coker JA, Knobbe JE, Truong DC, Yu H, Lin YS, Nimmo SL, Duerfeldt AS. Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial Acyldepsipeptides. ACS Med Chem Lett. 2017 Nov 09; 8(11):1171-1176. PMID: 29152050.
      View in: PubMed
    6. Crowley VM, Khandelwal A, Mishra S, Stothert AR, Huard DJ, Zhao J, Muth A, Duerfeldt AS, Kizziah JL, Lieberman RL, Dickey CA, Blagg BS. Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold. J Med Chem. 2016 Apr 14; 59(7):3471-88. PMID: 27003516.
      View in: PubMed
    7. Lavey NP, Coker JA, Ruben EA, Duerfeldt AS. Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease P. J Nat Prod. 2016 Apr 22; 79(4):1193-7. PMID: 26967980.
      View in: PubMed
    8. Di XJ, Wang YJ, Han DY, Fu YL, Duerfeldt AS, Blagg BS, Mu TW. Grp94 Protein Delivers ?-Aminobutyric Acid Type A (GABAA) Receptors to Hrd1 Protein-mediated Endoplasmic Reticulum-associated Degradation. J Biol Chem. 2016 Apr 29; 291(18):9526-39. PMID: 26945068.
      View in: PubMed
    9. Anderson ED, Duerfeldt AS, Zhu K, Glinkerman CM, Boger DL. Cycloadditions of noncomplementary substituted 1,2,3-triazines. Org Lett. 2014 Oct 03; 16(19):5084-7. PMID: 25222918.
      View in: PubMed
    10. Duerfeldt AS, Boger DL. Total syntheses of (-)-pyrimidoblamic acid and P-3A. J Am Chem Soc. 2014 Feb 05; 136(5):2119-25. PMID: 24410439.
      View in: PubMed
    11. Wolfe AL, Duncan KK, Lajiness JP, Zhu K, Duerfeldt AS, Boger DL. A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding. J Med Chem. 2013 Sep 12; 56(17):6845-57. PMID: 23944748.
      View in: PubMed
    12. Suntharalingam A, Abisambra JF, O'Leary JC, Koren J, Zhang B, Joe MK, Blair LJ, Hill SE, Jinwal UK, Cockman M, Duerfeldt AS, Tomarev S, Blagg BS, Lieberman RL, Dickey CA. Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism. J Biol Chem. 2012 Nov 23; 287(48):40661-9. PMID: 23035116.
      View in: PubMed
    13. Duerfeldt AS, Peterson LB, Maynard JC, Ng CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y, Nicchitta CV, Blagg BS. Development of a Grp94 inhibitor. J Am Chem Soc. 2012 Jun 13; 134(23):9796-804. PMID: 22642269.
      View in: PubMed
    14. Kusuma BR, Duerfeldt AS, Blagg BS. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg Med Chem Lett. 2011 Dec 01; 21(23):7170-4. PMID: 22014546.
      View in: PubMed
    15. Duerfeldt AS, Blagg BS. Hsp90 inhibition: elimination of shock and stress. Bioorg Med Chem Lett. 2010 Sep 01; 20(17):4983-7. PMID: 20656483.
      View in: PubMed
    16. Jadhav VD, Duerfeldt AS, Blagg BS. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorg Med Chem Lett. 2009 Dec 15; 19(24):6845-50. PMID: 19896848.
      View in: PubMed
    17. Duerfeldt AS, Brandt GE, Blagg BS. Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Org Lett. 2009 Jun 04; 11(11):2353-6. PMID: 19435295.
      View in: PubMed
    18. Duerfeldt AS, Blagg BS. Hydrating for resistance to radicicol. ACS Chem Biol. 2009 Apr 17; 4(4):245-7. PMID: 19371133.
      View in: PubMed
    Duerfeldt's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description